These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 29891789)
1. Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects. Zayed MF; Ahmed S; Ihmaid S; Ahmed HEA; Rateb HS; Ibrahim SRM Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29891789 [TBL] [Abstract][Full Text] [Related]
2. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
3. Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization. Zayed MF; Rateb HS; Ahmed S; Khaled OA; Ibrahim SRM Molecules; 2018 Jul; 23(7):. PubMed ID: 30002297 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects. Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968 [TBL] [Abstract][Full Text] [Related]
11. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. Soliman AM; Alqahtani AS; Ghorab M J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303 [TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities. El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484 [TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis, cytotoxicity and radiosensitization by novel 3,4-dihydroquinazolinone derivatives. Soliman AM; Khalil A; Ramadan E; Ghorab MM Bioorg Med Chem Lett; 2021 Oct; 49():128308. PubMed ID: 34363937 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743 [TBL] [Abstract][Full Text] [Related]
15. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR Abo Al-Hamd MG; Tawfik HO; Abdullah O; Yamaguchi K; Sugiura M; Mehany ABM; El-Hamamsy MH; El-Moselhy TF J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241674. PubMed ID: 37548154 [TBL] [Abstract][Full Text] [Related]
17. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967 [TBL] [Abstract][Full Text] [Related]
18. The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization. Ihmaid S; Ahmed HEA; Zayed MF Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385728 [TBL] [Abstract][Full Text] [Related]
19. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD. Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187 [TBL] [Abstract][Full Text] [Related]
20. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line. Sobh EA; Khalil NA; Faggal SI; Hassan MSA Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]